Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib + bevacizumab
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Niraparib + bevacizumab is a combination therapy used primarily as maintenance treatment in advanced ovarian cancer. Niraparib is an orally active small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), specifically targeting PARP-1 and PARP-2, which are enzymes involved in DNA repair. By inhibiting these enzymes, niraparib induces synthetic lethality in cancer cells with homologous recombination deficiency, such as those with BRCA mutations[3][6]. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply[4]. The combination has shown improved progression-free survival and durable overall survival without cumulative toxicity in patients with newly diagnosed advanced ovarian cancer who have responded to first-line platinum-based chemotherapy plus bevacizumab[1][2][8].
- Other names
- niraparib + bevacizumab
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on niraparib + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib + bevacizumab.